Periodic Reporting for period 1 - GWAFH (Emulsar: give the world appetite for health.)
Période du rapport: 2015-02-01 au 2015-07-31
Emulsar is an innovative SME founded in 2004. Emulsar invented a breakthrough emulsion technology that allows the designing and manufacturing of disruptive innovations to revolutionize health and nutrition.
Our ambition is to develop a a new generation protein ingredient for Oral Nutritional Supplements (ONS), using our innovative nanotechnology process.
Malnutrition is most commonly found in association with disease and can affect all age groups, from older adults to young children. ONS are defined as foods for special medical purposes that are specially formulated to meet the underlying nutritional deficiencies of a specific disease and are used in all healthcare settings across Europe and the World. ONS represent a vital element of patient care and can help to reduce hospital stays.
Malnutrition is widespread in Europe and it is estimated that 33 million people are at risk, a burden estimated to cost around 170 billion euro for the EU. Malnutrition has clinical and financial consequences, both for individuals and society as a whole.
The main obstacle for ONS is the huge lack of treatment compliance that dramatically limits effectiveness. Overall average compliance with ONS was only 50% for hospital patients. Improving compliance is the key to optimizing the clinical effectiveness of ONS.
Studies from European and North American countries show that compliance becomes significantly higher with smaller volume, energy-dense ONS. A higher frequency of a lower volume ONS during medication rounds significantly increased patient consumption. This indicates that small volume, nutritional and energy-dense ONS are an effective solution for improving nutritional intake.
Our ambition is to develop a a new generation protein ingredient for Oral Nutritional Supplements (ONS), using our innovative nanotechnology process.
Malnutrition is most commonly found in association with disease and can affect all age groups, from older adults to young children. ONS are defined as foods for special medical purposes that are specially formulated to meet the underlying nutritional deficiencies of a specific disease and are used in all healthcare settings across Europe and the World. ONS represent a vital element of patient care and can help to reduce hospital stays.
Malnutrition is widespread in Europe and it is estimated that 33 million people are at risk, a burden estimated to cost around 170 billion euro for the EU. Malnutrition has clinical and financial consequences, both for individuals and society as a whole.
The main obstacle for ONS is the huge lack of treatment compliance that dramatically limits effectiveness. Overall average compliance with ONS was only 50% for hospital patients. Improving compliance is the key to optimizing the clinical effectiveness of ONS.
Studies from European and North American countries show that compliance becomes significantly higher with smaller volume, energy-dense ONS. A higher frequency of a lower volume ONS during medication rounds significantly increased patient consumption. This indicates that small volume, nutritional and energy-dense ONS are an effective solution for improving nutritional intake.
We therefore aim to develop a new type of protein ingredient that makes it possible to reduce by up to 2 or 3 times the volume of current ONS, whilst maintaining the same nutritional content. Our breakthrough Protein plus ingredient will offer a clear market advantage to ONS manufacturers compared with existing products and represents a rapid growth opportunity for Emulsar.
Outcomes of phase 1 :
• ONS is the most valuables functional food products in terms of nutrition impact and business opportunity for Europe & the world ;
• We have produced lab prototypes with encouraging 1st results;
• IP strategy have been design and freedom to operate looks open;
• Market data are promising :
o ONS market : 10$bn / 5 big players (Europe and US)
• We have built a strong business plan to go to phase 2…
• ONS is the most valuables functional food products in terms of nutrition impact and business opportunity for Europe & the world ;
• We have produced lab prototypes with encouraging 1st results;
• IP strategy have been design and freedom to operate looks open;
• Market data are promising :
o ONS market : 10$bn / 5 big players (Europe and US)
• We have built a strong business plan to go to phase 2…